Correlation Between X4 Pharmaceuticals and Summit Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both X4 Pharmaceuticals and Summit Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining X4 Pharmaceuticals and Summit Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between X4 Pharmaceuticals and Summit Therapeutics PLC, you can compare the effects of market volatilities on X4 Pharmaceuticals and Summit Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in X4 Pharmaceuticals with a short position of Summit Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of X4 Pharmaceuticals and Summit Therapeutics.

Diversification Opportunities for X4 Pharmaceuticals and Summit Therapeutics

0.35
  Correlation Coefficient

Weak diversification

The 3 months correlation between XFOR and Summit is 0.35. Overlapping area represents the amount of risk that can be diversified away by holding X4 Pharmaceuticals and Summit Therapeutics PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Summit Therapeutics PLC and X4 Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on X4 Pharmaceuticals are associated (or correlated) with Summit Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Summit Therapeutics PLC has no effect on the direction of X4 Pharmaceuticals i.e., X4 Pharmaceuticals and Summit Therapeutics go up and down completely randomly.

Pair Corralation between X4 Pharmaceuticals and Summit Therapeutics

Given the investment horizon of 90 days X4 Pharmaceuticals is expected to generate 2.1 times less return on investment than Summit Therapeutics. In addition to that, X4 Pharmaceuticals is 1.2 times more volatile than Summit Therapeutics PLC. It trades about 0.05 of its total potential returns per unit of risk. Summit Therapeutics PLC is currently generating about 0.12 per unit of volatility. If you would invest  780.00  in Summit Therapeutics PLC on September 26, 2024 and sell it today you would earn a total of  1,087  from holding Summit Therapeutics PLC or generate 139.36% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

X4 Pharmaceuticals  vs.  Summit Therapeutics PLC

 Performance 
       Timeline  
X4 Pharmaceuticals 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in X4 Pharmaceuticals are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Even with relatively unsteady basic indicators, X4 Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point.
Summit Therapeutics PLC 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Summit Therapeutics PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's primary indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

X4 Pharmaceuticals and Summit Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with X4 Pharmaceuticals and Summit Therapeutics

The main advantage of trading using opposite X4 Pharmaceuticals and Summit Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if X4 Pharmaceuticals position performs unexpectedly, Summit Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Summit Therapeutics will offset losses from the drop in Summit Therapeutics' long position.
The idea behind X4 Pharmaceuticals and Summit Therapeutics PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Other Complementary Tools

Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk